---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-023916"
form_type: "8-K"
ticker: "PHIO"
cik: "0001533040"
company_name: "Phio Pharmaceuticals Corp."
filed_at: "2026-07-21T11:07:31+00:00"
generated_at: "2026-07-21T11:10:23.825593+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Phio Pharmaceuticals appoints Dr. R. Todd Plott to Board of Directors

## Summary
- Board size increased to six members; Dr. Plott appointed effective July 20, 2026 until 2026 annual meeting.
- Dr. Plott is a board-certified dermatologist with 30+ years experience and former FDA advisory committee member.
- He will receive standard non-employee director compensation and indemnification agreement.
- Appointment supports advancement of PH-762 for squamous cell carcinoma, per CEO Robert Bitterman.

## SEC filing metadata
- accession: 0001437749-26-023916
- form_type: 8-K
- ticker: PHIO
- cik: 0001533040
- company_name: Phio Pharmaceuticals Corp.
- filed_at: 2026-07-21T11:07:31+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533040/000143774926023916/0001437749-26-023916-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533040/000143774926023916/phio20260717_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-023916
- JSON: https://secwatch.observer/filing/0001437749-26-023916.json
- Plain text: https://secwatch.observer/filing/0001437749-26-023916.txt

## Key facts
- Executive change
  R. Todd Plott was appointed as Director at Phio Pharmaceuticals Corp..
  - Action: appointed
  - Role: Director
  source text: Effective as of July 20, 2026, the Board of Directors (the “Board”) of Phio Pharmaceuticals Corp. (the “Company”) increased the size of the Board to six members and appointed R. Todd Plott, M.D. to serve on the Board until the 2026 annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1533040/000143774926023916/0001437749-26-023916-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.